Journal of the American Society of Nephrology, Vol 2, 1697-1703, Copyright © 1992 by American Society of Nephrology

REGULAR ARTICLES

Atrial natriuretic peptide and urinary cyclic guanosine monophosphate in patients with chronic heart failure

WT Abraham, J Hensen, JK Kim, J Durr, EJ Lesnefsky, BM Groves and RW Schrier
Department of Medicine, University of Colorado School of Medicine, Denver 80262.

Circulating concentrations of human atrial natriuretic peptide (hANP) are elevated in patients with heart failure; however, the natriuretic effect of hANP is blunted in these patients. In this study, the relationship between urinary cGMP, the second messenger for the natriuretic effect of hANP in vivo, and endogenous hANP was examined in six patients with heart failure and four normal subjects. In addition, right heart catheterization for the determination of central hemodynamics was performed in the heart failure patients. The heart failure patients were in New York Heart Association Classes II to IV and were receiving no medications at the time of the study. Supine plasma hANP and urinary cGMP concentrations were determined on two occasions in each subject, as were right and left atrial pressures in the heart failure patients. At the time of study, the patients were in positive sodium balance, and control subjects were in normal sodium balance. Plasma hANP and urinary cGMP excretion rates were elevated in heart failure patients as compared with those in controls: hANP, 139.0 +/- 42.0 versus 22.0 +/- 6.1 pg/mL (P less than 0.05); urinary cGMP, 1.14 +/- 0.31 versus 0.35 +/- 0.05 nmol/min (P less than 0.05). In heart failure patients, right atrial pressure correlated positively with plasma hANP (r = 0.96; P less than 0.01) and urinary cGMP concentrations (r = 0.93; P less than 0.05) and the excretion rate (r = 0.92; P less than 0.05). Moreover, plasma hANP was strongly correlated with urinary cGMP concentration (r = 0.91; P less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				W. Wang, C. Li, L. N. Nejsum, H. Li, S. W. Kim, T.-H. Kwon, T. E. N. Jonassen, M. A. Knepper, K. Thomsen, J. Frokiaer, et al. Biphasic effects of ANP infusion in conscious, euvolumic rats: roles of AQP2 and ENaC trafficking Am J Physiol Renal Physiol, February 1, 2006; 290(2): F530 - F541. [Abstract] [Full Text] [PDF]

				K. H Chee, K. Amudha, N. A Hussain, H. K Haizal, A.-M. J Choy, and C. C Lang Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 140 - 148. [Abstract] [PDF]

				R. W. Schrier and W. T. Abraham Hormones and Hemodynamics in Heart Failure N. Engl. J. Med., August 19, 1999; 341(8): 577 - 585. [Full Text] [PDF]

				M. Bogdan, M. Humbert, J. Francoual, C. Claise, P. Duroux, G. Simonneau, and A. Lindenbaum Urinary cGMP concentrations in severe primary pulmonary hypertension Thorax, December 1, 1998; 53(12): 1059 - 1062. [Abstract] [Full Text]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673